National Comprehensive Cancer Network



About NCCN

Acute Myeloid Leukemia Panel - Disclosures as of 5/23/2013

View NCCN Management Team Disclosures | View NCCN Guidelines Staff Disclosures | View NCCN ORP Staff Disclosures

Panel Member Clinical Research Support Advisory Boards, Speakers Bureau, Expert Witness, or Consultant Patent, Equity, or Royalty Other Date Completed

Camille N. Abboud, MD

None

ARIAD Pharmaceuticals, Inc.;
Teva

None

None

4/5/2013

Jessica Altman, MD

ARIAD Pharmaceuticals, Inc.;
Bristol-Myers Squibb Company;
GlaxoSmithKline;
Millennium Pharmaceuticals, Inc.;
Astellas;
Clavis;
Cyclacel;
CytRx;
Lilly Pharmaceuticals

ARIAD Pharmaceuticals, Inc.;
Bristol-Myers Squibb Company;
Celgene Corporation;
Genoptix

None

None

5/19/2013

Frederick R. Appelbaum, MD

None

None

None

None

3/26/2013

Daniel A. Arber, MD

None

US Diagnostic Standards

None

None

4/29/2013

Eyal Attar, MD

None

Celgene Corporation;
Jannsen Pharmaceutica Products, LP

None

None

2/7/2013

Uma Borate, MD

GlaxoSmithKline

None

None

None

8/24/2012

Steven E. Coutre, MD

None

Celgene Corporation

None

None

5/16/2013

Lloyd E. Damon, MD

Talon;
Sunesis Pharmaceuticals, Inc.

None

None

None

2/19/2013

Lauren Gallagher, RPh, PhD

None

None

None

None

6/5/2012

Kristina M. Gregory, RN, MSN, OCN

None

None

None

None

10/23/2012

Jeffrey Lancet, MD

Celgene Corporation

Celgene Corporation;
Spectrum Pharmaceuticals

None

None

8/6/2012

Lori J. Maness, MD

Cyclacel, LTD

None

None

None

3/9/2012

Guido Marcucci, MD

None

None

None

None

8/15/2012

Michael G. Martin, MD

None

None

None

None

10/18/2012

Joan S. McClure, MS

None

None

None

None

7/23/2012

Michael M. Millenson, MD, FACP

None

None

None

None

2/22/2013

Joseph O. Moore, MD

ARIAD Pharmaceuticals, Inc.;
Genentech, Inc.;
Novartis Pharmaceuticals Corporation

Amgen Inc.;
Genentech, Inc.;
Novartis Pharmaceuticals Corporation

None

None

8/24/2012

Maoko Naganuma, MSc

None

None

None

None

2/28/2013

Margaret R. O'Donnell, MD

National Cancer Institute

None

None

None

8/17/2011

Farhad Ravandi, MD

Bayer HealthCare;
Celgene Corporation;
Merck & Co., Inc.;
Sunesis Pharmaceuticals, Inc.

Bayer HealthCare;
Cephalon, Inc.;
Eisai Inc.;
Genzyme Corporation;
Novartis Pharmaceuticals Corporation;
Sunesis Pharmaceuticals, Inc.

None

None

11/3/2012

Paul J. Shami, MD

Eisai Inc.;
Genzyme Corporation

ARIAD Pharmaceuticals, Inc.;
Novartis Pharmaceuticals Corporation

None

None

1/28/2013

B. Douglas Smith, MD

None

ARIAD Pharmaceuticals, Inc.;
Clavis;
TEVA

None

None

1/19/2013

Richard M. Stone, MD

Celgene Corporation;
Novartis Pharmaceuticals Corporation;
Sunesis Pharmaceuticals, Inc.

ARIAD Pharmaceuticals, Inc.;
Celgene Corporation;
Genzyme Corporation

None

None

10/11/2011

Stephen A. Strickland, MD

GlaxoSmithKline;
Novartis Pharmaceuticals Corporation;
Ambit;
Astellas Pharma US;
Celator Pharmaceuticals;
Cyclacel Pharmaceuticals;
sanofi-aventis U.S.;
Sunesis Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH;
Sunesis Pharmaceuticals, Inc.

None

None

3/25/2013

Martin S. Tallman, MD

None

Genzyme Corporation

None

None

10/16/2012

Eunice S. Wang, MD

None

None

None

None

8/20/2012

 

About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0260
Copyright © 2012 National Comprehensive Cancer Network, All Rights Reserved